MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...
MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical ...
NSAIDs should be considered as first-line treatment for children with acute pain, with ketamine and mid- to high-potency opioids as other effective options.
Intra-articular corticosteroid injection is associated with a reduced use of pain medications, including opioid combinations, ...
Additionally, the results of one study suggested that topical NSAIDs may be more effective ... followed by ketamine or mid- to high-potency opioids. She said more research is needed to evaluate ...
Scilex (NASDAQ:SCLX – Get Free Report) is projected to release its earnings data before the market opens on Monday, March ...
MIAMI, FL / ACCESS Newswire / March 4, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on ...
The drugs are listed in alphabetical order. Aprepitant oral suspension: Merck reported a shortage of Emend, its aprepitant oral suspension. Merck did not provide a reason for the shortage. The ...
Headache? Take a painkiller! Joint pain? Take a painkiller! In our day-to-day lives, we reach for a painkiller for immediate relief for pain of any kind and thi ...
"We strive to provide these patients with a non-opioid treatment option that combines ... Grünenthal already sells a topical capsaicin product called Qutenza for post-shingles nerve pain and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results